Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations

British Journal of Cancer

Volumn 91, Issue 11, 2004, Pages 1911-1915

  Whittemore, A S ^a   Balise, R R ^a   Pharoah, P D P ^b   DiCioccio, R A ^c   Oakley Girvan, I ^d   Ramus, S J ^e   Daly, M ^f   Usinowicz, M B ^a   Garlinghouse Jones, K ^a   Ponder, B A J ^g   Buys, S ^h   Senie, R ⁱ   Andrulis, I ^j   John, E ^d   Hopper, J L ^k   Piver, M S ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d NORTHERN CALIFORNIA CANCER CENTER   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h UNIVERSITY OF UTAH   (United States)

ⁱ Columbia University ^*  (United States)

^j CANCER CARE ONTARIO   (Canada)

^k UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

BRCA1; BRCA2; Oral contraceptives, ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; ORAL CONTRACEPTION; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; REGRESSION ANALYSIS; SELF REPORT;

ADULT; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 19944426928     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602239     Document Type: Article

References (21)

1. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles D, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Eerola H, Nevanlinna H, Syrjakoski K, Kalliomeni O-P, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with mutations in BRCA1 and BRCA2 detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117-1130
2. Breslow NE, Day NE (1980) Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ, (32): 5-338
3. Del Tito Jr BJ, Poff III HE, Novotny MA, Cartledge DM, Walker II RI, Earl CD (1998) Automated fluorescent analysis procedure for enzymatic mutation detection. Clin Chem 44: 731-739
4. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M, Breast Cancer Linkage Consortium (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689
5. Gayther SA, Russell P, Harrington P, Antoniou A, Easton DF, Ponder BAJ (1999) The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 65: 1021-1029
6. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, Santella RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara D, The Breast Cancer Family Registry (2004) The Breast Cancer Family Registry (Breast CFR): an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6: R375-R389, (http://www.cfr.epi.uci.edu)
7. La Vecchia C, Franceschi S (1999) Oral contraceptives and ovarian cancer. Eur J Cancer Prev 8: 297-304
8. McGuire V, Felberg A, Mills M, Ostrow KL, DiCioccio RA, John EM, West DW, Whittemore AS (2004) Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 160: 613-618
9. Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, Andrulis IL, West DW, Southey MC, Giles GG, McCredie MRE, Hopper JL, Whittemore AS, for the Breast Cancer Family Registry (2004) Oral contraceptive use and risk of early-onset breast cancer in carriers and non-carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (in press)
10. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baruch G, Fishman A, Menczer J, Ebbers SM, Tucker MA, Wacholder S, Struewing JP, Friedman E, Piura B (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345: 235-240
11. Modan B, Wacholder S (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345: 1707 (letter)
12. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94: 1773-1779
13. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BA (1998) Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339: 424-428
14. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen SL (2001a) Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 357: 1467-1470
15. Narod SA, Sun P, Risch HA (2001b) Ovarian cancer, oral contraceptives, and BRCA mutations. N Engl J Med 345: 1706-1707
16. National Human Genome Research Project (2002) Breast cancer information core: an open access on-line breast cancer mutation data base, 2002 (Accessed 15 May, 2004, at http://research.nhgri.nih.gov/bic/)
17. Osborne RH, Hopper JL, Kirk JA, Chenevix-Trench G, Thorne HJ, Sambrook JF, kConFab: a research resource of Australasian breast cancer families (2000) Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. Med J Aust 172: 463-464
18. Scott CL, Jenkins MA, Southey MC, Davis TA, Leary JA, Phillipes K-A, Hopper JL, for the Kathleen Cuningham Foundation for Familial Breast Cancer (kConFab) (2003) Average age-specific risk of breast cancer associated with germline mutations in BRCA1 and BRCA2 estimated from families attending Australian Family Cancer Clinics. Hum Genet 112: 542-551
19. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408
20. Ursin G, Henderson BE, Haile RW, Pike MC, Zhou N, Diep A, Bernstein L (1997) Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 57: 3678-3681
21. Whittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer Group (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of twelve US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136: 1184-1203